Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trials Insight: 700027165

Trial Profile

Clinical Trials Insight: 700027165

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Apr 2008

At a glance

  • Drugs Sparsentan (Primary)
  • Indications Diabetic nephropathies; Hypertension
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Pharmacopeia
  • Most Recent Events

    • 15 Apr 2008 Interim results will be reported at ASH 2008 (abstract P-14).
    • 04 Dec 2007 Additional positive safety results reported in a Pharmacopeia media release.
    • 29 Sep 2007 Early results have indicated no safety or tolerability issues. As a result, the study will be expanded to include a 1000mg dose. The Company expects to report findings from this dose later in 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top